|
gptkbp:instanceOf
|
gptkb:protein
gptkb:drug
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
2014
|
|
gptkbp:ATCCode
|
A16AA06
|
|
gptkbp:brand
|
gptkb:Myalept
|
|
gptkbp:CASNumber
|
gptkb:218949-48-5
|
|
gptkbp:contraindication
|
generalized lipodystrophy with anti-leptin antibodies
|
|
gptkbp:developedBy
|
gptkb:Amylin_Pharmaceuticals
|
|
gptkbp:drugClass
|
hormone
|
|
gptkbp:hasMolecularFormula
|
C714H1134N196O218S2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
metreleptin
|
|
gptkbp:indication
|
gptkb:congenital_generalized_lipodystrophy
acquired generalized lipodystrophy
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
leptin receptor agonist
|
|
gptkbp:molecularWeight
|
16,150 Da
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:product
|
gptkb:recombinant_methionyl_human_leptin
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
abdominal pain
headache
|
|
gptkbp:UNII
|
QGC2TM8Z1S
|
|
gptkbp:usedFor
|
treatment of lipodystrophy
|
|
gptkbp:bfsParent
|
gptkb:familial_partial_lipodystrophy
|
|
gptkbp:bfsLayer
|
7
|